DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Clinical trial NCT07707895 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07707895
Sponsor: Boehringer Ingelheim
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer Large Cell Neuroendocrine Lung Carcinoma Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

Start date: 2026-08-26
Primary completion: 2030-04-26
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.